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fi ndings. If the podocytes are the pri-
mary excreters of IL-18, where are the 
activated Th 1 cells? What is the stimulus 
for production and secretion of IL-18? 
Are the podocytes and other renal cells 
perhaps endocytosing IL-18 rather than 
producing it? Alternatively, we must ask 
whether IL-18 production by these cells 
is instead a consequence rather than an 
initiator of neutrophil activation. As 
we know that proteinase 3 is capable of 
activating pro-IL-18 in vitro, what are 
the functional consequences of this in 
proteinase 3-ANCA disease? It would 
be expected that any cytokine secreted 
by podocytes would pass into the urine 
rather than cross the glomerular base-
ment membrane opposite to the normal 
direction of fi ltration; direct secretion by 
the podocytes into the vasculature would 
truly be a novel finding. Regardless, 
this report reveals that podocytes may 
be direct participators in the immune 
dysfunction of ANCA disease, and that 
IL-18 may be responsible for neutrophil 
priming in vivo.
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Fibroblast growth factor 23: the 
making of a hormone
SC Schiavi1
Fibroblast growth factor 23 (FGF23) modulates serum phosphate and 
1α,25-dihydroxyvitamin D3 levels.  FGF23 expression is in turn regulated 
by 1α,25-dihydroxyvitamin D3 and dietary phosphate load, and is 
strikingly elevated during renal progression.   In this issue, Nagano and 
colleagues report that FGF23 can be modulated by intermittently high 
dietary phosphate in the presence of compromised renal function.  
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Over the past several years, accumulat-
ing evidence has documented the role of 
fi broblast growth factor 23 (FGF23) in 
the control of phosphate and vitamin D 
homeostasis. Th ese data show that FGF23 
acts in accordance with the defi nition of a 
hormone: a circulating protein that targets 
specifi c tissues distant from its site of pro-
duction. FGF23 acts directly on the kidney 
to regulate the synthesis of 1α,25-dihy-
droxyvitamin D3 and the surface expres-
sion of the sodium phosphate transporters 
NaPi-IIa and -IIc.1–4 Several reports now 
demonstrate that serum FGF23 con-
centrations increase both in response to 
dietary phosphate load with normal renal 
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function and in response to increasing 
serum phosphate levels associated with 
progressive renal failure.1,3 Despite this 
body of data, a debate continues regard-
ing the physiological relevance of FGF23 
as a major regulator of phosphate home-
ostasis. In particular, it has been argued 
that elevated FGF23 in renal disease is a 
consequence of reduced renal clearance 
and therefore may not play a direct role 
in the progression of renal disease and its 
associated complications.
The study presented in this issue by 
Nagano et al.5 represents an important 
advancement beyond the previously 
identifi ed association of elevated FGF23, 
phosphate, and parathyroid hormone 
(PTH) levels in renal disease.1,3,4 By using 
a model of severe chronic kidney disease 
and including an experimental arm in 
which phosphate levels were regulated 
by intermittent dosing of the phosphate 
binder sevelamer hydrochloride, the 
authors have provided convincing evi-
dence that FGF23 serum concentrations 
were infl uenced by elevated dietary and 
serum phosphate. Importantly, the data 
argue that decreased renal function can-
not adequately explain the dramatic rise 
in FGF23 serum concentrations associ-
ated with renal insuffi  ciency, as changes 
in serum FGF23 levels were observed in 
the presence of severely compromised kid-
ney function. Together with the substan-
tial data demonstrating direct actions of 
FGF23 on renal phosphate excretion, these 
results imply that the levels of FGF23, like 
those of PTH, may rise in response to the 
increasing pressure to excrete phosphate.
Th e study by Nagano et al.5 also dem-
onstrates another important feature of 
FGF23 regulation: that FGF23 serum 
levels are modified rather slowly in 
response to increased dietary phosphate. 
Although changes in serum phosphate 
and PTH occurred 1 day after sevela-
mer treatment or removal, there was an 
additional lag before FGF23 levels were 
altered. Th e mechanism triggering the 
slow regulation of FGF23 is not clear, but 
the delay suggests that phosphate does 
not directly control FGF23 synthesis. 
Th is result implies that FGF23’s function 
is most important as a chronic rather than 
an acute response to changes in phos-
phate and partially explains the need for 
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two phosphate-regulating hormones. 
Such an argument makes further sense 
when one considers the opposing actions 
of FGF23 and PTH in the regulation of 
1α,25-dihydroxyvitamin D3 synthesis. 
PTH classically induces synthesis of 1α-
hydroxylase, whereas FGF23 inhibits its 
synthesis.1,4 Th us, it has been proposed 
that FGF23 counterbalances the actions of 
PTH by keeping a tighter rein on vitamin 
D and serum calcium levels in the face of 
sustained phosphate challenges.6
The working hypothesis (Figure 1) 
incorporates the known actions of FGF23, 
and the fi nding that FGF23 elevation in 
response to increased phosphate is delayed 
relative to PTH, into the accepted dogma 
defining the mechanisms of mineral 
homeostasis. In this model, (1) increased 
dietary phosphate uptake results in a rise 
in serum phosphate concentrations and 
subsequent increased PTH secretion from 
the parathyroid gland. (2) PTH induces 
phosphate excretion by downregulating 
the renal sodium phosphate transporter 
NaPi-IIa. (3) Simultaneously, PTH 
induces synthesis of 1α,25-dihydroxyvi-
tamin D3 by upregulating 1α-hydroxylase. 
(4) 1α,25-Dihydroxyvitamin D3 promotes 
a rise in serum calcium by increasing 
intestinal calcium absorption, calcium and 
phosphate release from bone, and calcium 
reabsorption in the kidney. (5) FGF23 
synthesis in bone cells is also induced by 
increased production of 1α,25-dihydrox-
yvitamin D3, whereas (6) PTH synthesis 
is inhibited by rising calcium levels. (7) 
Increased production of FGF23 sustains 
the dampened renal phosphate reabsorp-
tion while (8) preventing the unchecked 
induction of 1α,25-dihydroxyvitamin D3 
synthesis and calcium mobilization.
Th e above model should be approached 
not simply from a phosphate-centric view-
point but rather as a homeostatic path-
way necessary for maintenance of both 
calcium and phosphate. Th us, according 
to the proposed paradigm, PTH actions 
would predominate when phosphate lev-
els were high and calcium levels were low, 
whereas FGF23 actions would predomi-
nate when both phosphate and calcium 
levels were high. Th is hypothesis would 
further suggest a currently unreported 
role for elevated calcium in the regula-
tion of FGF23.
If FGF23 is important for normal 
regulation of mineral homeostasis, then 
dysregulation of this hormone should 
have pathological consequences. Indeed, 
overexpression of FGF23 in the pres-
ence of a functioning kidney in humans 
and animal models results in hypophos-
phatemia, rickets, and osteomalacia.1,2 
In renal disease, declining vitamin D 
production and increased PTH secretion 
due to hyperparathyroidism contribute to 
renal osteodystrophy and vascular calcifi -
cation. FGF23 may indirectly contribute 
to these processes through its regulation 
of vitamin D and PTH. FGF23’s inhibi-
tory action on 1α-hydroxlyase, and the 
inverse relationship between FGF23 and 
declining 1α,25-dihydroxyvitamin D3, are 
consistent with the hypothesis that FGF23 
contributes to the progressive decrease in 
vitamin D commonly associated with 
chronic renal insuffi  ciency. Furthermore, 
a recent study used multiple linear regres-
sions and concluded that increased FGF23 
levels occur early in chronic kidney dis-
ease, before the development of serum 
mineral abnormalities, and are independ-
ently associated with serum phosphate, 
fractional excretion of phosphate, and 
calcitriol defi ciency.7
Although in vivo administration of 
FGF23 does not acutely promote PTH 
secretion, secondary hyperparathy-
roidism is generally associated with 
chronic FGF23 elevation in individu-
als with chronic renal insufficiency 
and in animal models with sustained 
elevated FGF23.1,3,7 Furthermore, cir-
culating FGF23 levels, rather than PTH 
levels, are most predictive of refractory 
hyperparathyroidism. Th e cumulative 
data currently suggest that FGF23 may 
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Figure 1 | Model depicting potential role of FGF23 in mineral homeostasis.  (a)  PTH 
actions initiate control of phosphate and calcium balance.  (b)  FGF23’s proposed function to 
counterbalance PTH regulation of vitamin D. 
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contribute to hyperparathyroidism indi-
rectly by downregulating 1α,25-dihy-
droxyvitamin D3, with the subsequent 
decrease in serum calcium enhancing 
PTH production.
It is unknown whether high FGF23 
levels contribute to altered bone and 
vascular health during renal disease. 
Physiological levels of circulating FGF23 
may in fact be protective against ectopic 
calcifi cations and vascular disease.8 In 
mice, FGF23 gene ablation results in 
soft  tissue calcifi cations. Human FGF23 
mutations that reduce functional levels 
of FGF23 protein cause tumoral calci-
nosis, a disease associated with severe 
ectopic calcifications.1 Thus, there is 
currently no evidence suggesting that 
elevated FGF23 has a direct impact on 
vascular calcifi cation.
Alternatively, FGF23 may play a role 
in renal osteodystrophy. Although a 
direct action of FGF23 on bone has not 
been rigorously demonstrated, cells of 
the osteoblast lineage produce FGF23, 
and high FGF23 levels are associated 
with osteomalacia. Th e possibility that 
FGF23 may directly control bone miner-
alization is consistent with an intriguing 
hypothesis that FGF23 coordinates renal 
phosphate handling to meet the needs of 
mineralization.9 Additional studies will 
be needed to clarify such a putative role 
for FGF23 as a general regulator or sen-
sor of bone mineralization, and how its 
subsequent dysregulation may contrib-
ute to mineralization defects associated 
with chronic kidney disease.
One critical piece of information 
that is still lacking is whether all of the 
FGF23 measured in serum from indi-
viduals with renal disease is biologically 
active. Taking our lessons from experi-
ences with the measurement of PTH, the 
existing enzyme-linked immunosorbent 
assays may not detect or distinguish all 
relevant forms of FGF23 in circulation. 
It remains to be determined whether 
fragments of FGF23 exist with altered or 
inhibitory functions that either interfere 
with or remain undetected by the cur-
rent assays.
Merely 5 years have passed since FGF23 
mutations were linked to phosphate dys-
regulation.10 Th e intervening time has 
brought rapid advances in the understand-
ing of FGF23 function, and with them a 
decline in the skepticism over the exist-
ence of yet another hormone controlling 
mineral homeostasis. Although questions 
remain, studies such as those presented by 
Nagano and colleagues5 bring us closer to 
a more complete understanding of min-
eral metabolism, allowing us to consider 
the eff ects of FGF23 alongside those of 
more traditional hormones. Move over, 
PTH and vitamin D — another hormone 
has arrived!
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